Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Michal Tsumer(Rambam Health Care Campus), Robin Joyce(Beth Israel Deaconess Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Rachal Barhad(Rambam Health Care Campus), Lynne Uhl(Hadassah Medical Center), Paul G. Richardson(Harvard University), Nikhil C. Munshi(Dana-Farber Cancer Institute), Karen Francoeur(Dana-Farber Cancer Institute), Brett Glotzbecker(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Jacob M. Rowe(Technion – Israel Institute of Technology), Baldev Vasir(Beth Israel Deaconess Medical Center), Katharine Conway(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Irit Avivi(Tel Aviv Sourasky Medical Center), Dilani Dombagoda(Beth Israel Deaconess Medical Center), Nancy Giallombardo(Beth Israel Deaconess Medical Center), Lina Bisharat(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), Tami Katz(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Donna Fitzgerald(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center)
Cited by 6
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k